Authoritative Report: 2020 Global Health Investment and Financing Record China's performance?

In 2020, the outbreak and pandemic of the new crown will not only affect the health and daily lives of people around the world, but also raise awareness of the importance of innovation in the healthcare industry for the maintenance of world health.
, the healthcare sector, whether it is early investment and financing, or late IPOs and M and A, are showing a "counter-current" trend.
, the prestigious Silicon Valley Bank (SVB) released its full-year 2020 investment and financing report, which has been publishing annual healthcare investment and financing for 10 years.
report notes that in 2020, a number of investment and financing indicators related to the health care industry are at an all-time high.
note that this year's report provides a separate analysis of China's investment and financing performance.
today, the Pharmaceutical Mingkang content team will share the highlights of this report with readers.
Healthcare venture capital raised a record amount, up 57% from last year, and in 2020, health venture capital raised a new record for the fourth year in a row, raising more than $16 billion, up 57% from 2019 and the largest increase since 2011.
a number of venture capital firms focused on investing in the healthcare industry have completed the creation of new investment funds, including well-known venture capital firms Atlas Venture, ARCH Venture, Flagship Venture and others.
the U.S. and Europe, investments completed by venture capital institutions rose 47 percent to $51 billion by 2020.
investment in all of the healthcare sub-sectors has broken records, with the venture capital-backed biopharma and diagnostic/tools industries performing well against the new crown pandemic.
sectors are also seeing the largest increase in investment in 2020 compared to 2019.
, HealthTech, which provides new models for patient therapy and clinical trials, has also been the focus of attention due to multiple social distances and home orders.
Biopharmaceutical Round A financing increased by 32% over last year, and the neuropathy sector received a sixfold increase in Biopharmaceutical Round A financing, which reached US$4.89 billion in 2020 (US/Europe), an increase of 32% compared to 2019.
investments are in oncology and platform companies.
is worth noting that investments in neurology are six times higher than in 2019.
further analysis of investments in the field of neurological disorders shows that companies focused on rare neurological disorders will be particularly active in 2020, with some results at different stages of the investment and financing process.
nearly half of them are developing small molecule drugs, which are commonly used to regulate protein function.
2020, $1.4 billion will be invested in gene therapy, using AAV vectors to deliver or knock out target genes.
in the field of neurological diseases, this treatment model has received the largest amount of investment, but also reflects the industry's recognition of the use of gene therapy to treat neuropathy potential.
in diagnostics/tools has been one of the focus of attention during the new crown pandemic, with investment in diagnostics/tools soaring by 78%.
$9.6 billion by 2020, with research and development tools accounting for 43%.
in diagnostic testing, GRAIL, Freenome and Thrive, three companies that conduct early cancer screening with liquid biopsies, are doing well.
GRAIL and Thrive were acquired by Illumina and Act Sciences, respectively.
china's medical and health risk investment and financing doubled, biopharmaceuticals led this year's Silicon Valley Bank issued investment and financing report in China's medical and health sector investment and financing situation of a thematic analysis.
In 2020, China's healthcare venture capital deals, sedcented by policies that encourage in-house innovation, totaled a record $12.1 billion, double the amount invested and financed in 2019.
, biomedicine, medical devices, diagnostics/tools have all increased by more than 100%.
in China, venture capital-backed start-ups rely mostly on the support of domestic investors, the most active of whom include Sequoia Capital, Qiming Ventures, Sequoia Capital and Lilly Asia Funds.
, oncology and platform technology are among the best in biomedicine, attracting $2.8 billion and $2.1 billion in venture capital investments, respectively.
the new crown outbreak, wind investment in the anti-infected sector has increased tenfold since 2019.
we look ahead to the investment and financing trends for healthcare in 2021? Silicon Valley Bank reports that investment and financing in some areas is likely to fall due to record performance in 2020, but will remain healthy.
in diagnostics/tools, Silicon Valley Bank predicts that 2021 could still be a record year.
addition, the report notes that the health technology sector will grow robustly in 2021 as integrated care models for virtual medicine, as well as virtual and face-to-face medicine, become mainstream during the pandemic.